Melanie Grace Huber

Array ( [id] => 17792147 [patent_doc_number] => 20220251238 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => BISPECIFIC ANTIGEN-BINDING CONSTRUCT AND PREPARATION METHOD AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/711121 [patent_app_country] => US [patent_app_date] => 2022-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5116 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17711121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17595367 [patent_doc_number] => 20220144940 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => ILT7 BINDING MOLECULES AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/350271 [patent_app_country] => US [patent_app_date] => 2021-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34393 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17350271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16512972 [patent_doc_number] => 20200392230 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => BISPECIFIC ANTI-CD3 X CD20 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/930933 [patent_app_country] => US [patent_app_date] => 2020-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11925 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 180 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15930933 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16376388 [patent_doc_number] => 20200325230 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => BTLA-BINDING ANTIBODIES FOR MODULATING IMMUNE RESPONSE AND TREATING DISEASE [patent_app_type] => utility [patent_app_number] => 16/836006 [patent_app_country] => US [patent_app_date] => 2020-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24408 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 604 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16836006 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18428743 [patent_doc_number] => 11673953 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-13 [patent_title] => DLL3 targeting chimeric antigen receptors and binding agents [patent_app_type] => utility [patent_app_number] => 16/802822 [patent_app_country] => US [patent_app_date] => 2020-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 44 [patent_no_of_words] => 38225 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16802822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15960565 [patent_doc_number] => 20200164034 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => METHODS FOR IMPROVING SEX-DIMORPHIC RESPONSES TO TARGETED THERAPY IN MELANOMA [patent_app_type] => utility [patent_app_number] => 16/663271 [patent_app_country] => US [patent_app_date] => 2019-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10354 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16663271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15990551 [patent_doc_number] => 20200171146 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => METHODS OF TREATING LUNG CANCER WITH A PD-1 AXIS BINDING ANTAGONIST, AN ANTIMETABOLITE, AND A PLATINUM AGENT [patent_app_type] => utility [patent_app_number] => 16/515848 [patent_app_country] => US [patent_app_date] => 2019-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51378 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16515848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15361023 [patent_doc_number] => 20200016276 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => ANTIBODY-DRUG CONJUGATES BASED ON GOLD COMPOUNDS [patent_app_type] => utility [patent_app_number] => 16/503958 [patent_app_country] => US [patent_app_date] => 2019-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5858 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16503958 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15293649 [patent_doc_number] => 20190389960 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => COMPOSITIONS AND METHODS FOR C1Q TARGETED THERAPY [patent_app_type] => utility [patent_app_number] => 16/450120 [patent_app_country] => US [patent_app_date] => 2019-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15572 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16450120 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14836273 [patent_doc_number] => 20190276537 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => Segregation Modulation for Immunotherapy [patent_app_type] => utility [patent_app_number] => 16/414937 [patent_app_country] => US [patent_app_date] => 2019-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3145 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16414937 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17844925 [patent_doc_number] => 11434278 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-06 [patent_title] => Protein-polymer-drug conjugates [patent_app_type] => utility [patent_app_number] => 16/382735 [patent_app_country] => US [patent_app_date] => 2019-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 13 [patent_no_of_words] => 52327 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16382735 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15586267 [patent_doc_number] => 20200069668 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor [patent_app_type] => utility [patent_app_number] => 16/355204 [patent_app_country] => US [patent_app_date] => 2019-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62250 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16355204 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15147881 [patent_doc_number] => 20190352418 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => ANTI-CD73 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/296532 [patent_app_country] => US [patent_app_date] => 2019-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 85811 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16296532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14778063 [patent_doc_number] => 20190263929 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => Antibodies Useful for Detection of Human Carcinoma Antigen [patent_app_type] => utility [patent_app_number] => 16/285805 [patent_app_country] => US [patent_app_date] => 2019-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11695 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16285805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17713517 [patent_doc_number] => 11377500 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-05 [patent_title] => Antibodies specific for CD70 and their uses [patent_app_type] => utility [patent_app_number] => 16/264485 [patent_app_country] => US [patent_app_date] => 2019-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29282 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16264485 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15408025 [patent_doc_number] => 20200024334 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => Heterodimeric proteins and preparation method thereof [patent_app_type] => utility [patent_app_number] => 16/255482 [patent_app_country] => US [patent_app_date] => 2019-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8056 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16255482 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14578629 [patent_doc_number] => 20190216923 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => METHODS AND COMBINATION THERAPY TO TREAT CANCER [patent_app_type] => utility [patent_app_number] => 16/244768 [patent_app_country] => US [patent_app_date] => 2019-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16244768 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14464313 [patent_doc_number] => 20190183796 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => COMBINATION TAXOID NANOEMULSION WITH IMMUNOTHERAPY IN CANCER [patent_app_type] => utility [patent_app_number] => 16/225629 [patent_app_country] => US [patent_app_date] => 2018-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12753 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16225629 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16267308 [patent_doc_number] => 20200268795 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => INTERFERON-GAMMA ATTENUATES ANTI-TUMOR IMMUNE RESPONSE TO CHECKPOINT BLOCKADE [patent_app_type] => utility [patent_app_number] => 16/646512 [patent_app_country] => US [patent_app_date] => 2018-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14857 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16646512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13774817 [patent_doc_number] => 20190000947 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-03 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 16/134422 [patent_app_country] => US [patent_app_date] => 2018-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48755 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16134422 [rel_patent_id] =>[rel_patent_doc_number] =>)